Tumor-associated macrophages are the most abundant immune cells in the tumor microenvironment and may express both anti-tumor and pro-tumor functions depending on their polarization towards an M1 (classical) or M2 (alternative) phenotype, respectively. This dual role has yet to be understood in many cancers, such as colon cancer, although it is known that pro-tumor functions include tumor growth, angiogenesis, immunosuppression, and matrix remodeling. Thus, tumorassociated macrophages have gained clinical momentum as cancer targets. To better understand the role of tumor-associated macrophages in the tumor microenvironment in response to various anti-cancer therapies, investigators typically implement an immunohistochemistry panel. However, immunohistochemistry protocols differ widely in their use of target surface markers, and many use intracellular antigens or only stain for single surface markers to quantify macrophage polarization, making reproducibility and study-to-study comparisons difficult. In response, we have developed a reliable and reproducible double immunostaining approach to quantify polarization of tumor-associated macrophages in murine tissue. Specifically, this immunohistochemistry staining protocol was developed for murine subcutaneous colon tumor allografts; however, this protocol can be readily modified to stain any murine tissue in allograft, xenograft, or orthotopic tumor models. This immunohistochemistry staining protocol is meant to be used and modified by investigators studying the causal effects between anti-cancer therapies and tumor-associated macrophages in murine tumors and to aid in reproducibility, consistency, and better study-to-study comparisons across the field.
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In most cancers, TAMs are skewed more towards the pro-tumor M2-phenotype (Yang and Zhang, 2017) ; therefore, TAMs have gained clinical momentum as immunotherapy targets for cancer. Currently, there are over 30 clinical trials targeting TAMs; strategies include reducing monocyte recruitment to the tumor and reprogramming M2-TAMs to M1-TAMs. Yang and Zhang provide a comprehensive review of TAM immunotherapy strategies (Yang and Zhang, 2017) . Still many other groups are actively investigating TAMs in the basic science and pre-clinical realms (Cassetta et al., 2016; He et al., 2017; Jarosz-Biej et al., 2018; Suarez-Lopez et al., 2018) . However, TAMs in some cancers, like colorectal cancer (CRC), simultaneously have both detrimental and beneficial effects on the patient (Zhong et al., 2018) .
The dual-role of TAMs in CRC has yet to be fully understood. It has recently been shown that macrophages induce resistance to fluorouracil-based chemotherapy, and that this TAM-induced resistance may contribute to the poor chemotherapy response in some CRC patients (Zhang et al., 2008; Zhang et al., 2016) . Currently, a gap in colon cancer research is how therapy affects TAMs in the colorectal TME, and, in turn, how altering TAM population and polarization affects tumor therapeutic response. Therefore, this immunohistochemistry staining protocol was developed to stain for TAMs in murine subcutaneous colon tumor allografts, although this protocol can be used for other murine tissue.
In this article, Balb/c mice were subcutaneously injected in the left flank with CT26 murine colon carcinoma cells. Tumors grew until they reached 75 mm 3 . Following three days of additional tumor growth, untreated tumors were dissected, flash-frozen in isopentane and liquid nitrogen, and stored at -80 °C until cryosectioning, and then sectioned at a thickness of 5 μm. The scope of this article is on macrophage immunohistochemistry of murine tumors, not on the tumor model itself. Therefore, this protocol can be readily modified to stain any murine tissue in allograft, xenograft, or orthotopic tumor models.
This direct immunohistochemistry staining method uses three primary-conjugated macrophage antibodies: anti-CD68, anti-CD80, and anti-CD206. CD68 is a pan-macrophage surface marker (Gordon et al., 2014) , CD80 is a cell surface marker for M1-type macrophages (Zhou et al., 2017) , and CD206 is a cell surface marker for M2-type macrophages (Kigerl et al., 2009 ). CD68, CD80, and CD206 are markers for other cell types as well but were chosen such that (CD68 + /CD80 + )-cells were considered M1-TAMs, (CD68 + /CD206 + )-cells were considered M2-TAMs, and (CD80 + /CD206 + )-cells were considered dendritic cells (DCs). Cells expressing all macrophage surface markers were considered to have a mixed M1-M2 phenotype (Figure 1 ).
With this simple and reproducible method, we are able to accurately stain for M1 and M2 macrophages. To ensure long-term relevancy and usability of this protocol, this work also provides an easy-to-follow mathematical analysis of antibody concentrations so that readers can easily modify and optimize this protocol for their specific test system. This work is relevant for investigators developing and/or testing TAM-targeting cancer immunotherapies in mice.
www.bio-protocol.org/e3106 DOI:10.21769/BioProtoc.3106 tumors were placed in a cryomold and covered completely in optimal cutting temperature (OCT). The cryomold with OCT and tumor was flash frozen in isopentane chilled in liquid nitrogen at -75 °C to -77 °C for at least 15 s and stored permanently in -80 °C until sectioning. The tumor was sectioned at 5 μm, although sections up to 10 μm are acceptable. Once sectioned, slides were stored for up to one month at -80 °C before staining. All antibody solutions and stained slides were handled in darkness. 13. Image the CD68-stained cells.
Materials and Reagents
Note: See the note under step A11 (Image the CD80-stained cells).
14.
Without moving tissue location, use the Texas Red filter and bring the CD206 + cells into focus. 15 . Image the CD206-stained cells.
Note: See the note under step A11 (Image the CD80-stained cells). 16 . Switch to a new tissue location and repeat Steps A10-A15. 17 . Acquire images from the desired amount of tissue locations. 
Notes
This protocol can be modified to include nuclear staining. Figure 6 shows a Balb/c-CT26 subcutaneous colon tumor allograft tissue section stained with DAPI and CD206 only. The proceeding calculations determine the volume of concentrated stock antibody to add to the macrophage antibody cocktail, and how many trials can be performed with these settings. 
